|
|
|
| Data mining on medication rules of Wu Yu in the treatment of advanced hepatocellular carcinoma |
| SONG Jinjie LI Zhongyu GUO Zhongning WU Yu |
| Department of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China |
|
|
|
Abstract Objective To investigate the medication rules of Professor Wu Yu in the treatment of advanced hepatocellular carcinoma. Methods Chinese medicine prescriptions of patients with advanced hepatocellular carcinoma treated in Outpatient Department of Professor Wu Yu in Xiyuan Hospital, China Academy of Chinese Medical Sciences from September 2017 to December 2018 were selected as research objects. Chinese medicine inheritance auxiliary platform of China Academy of Chinese Medical Sciences (V2.5) was used to count the drug use frequency and association rules, and the complex system entropy clustering was used for cluster analysis of core drugs to mine the core combinations and new prescriptions of drugs. Results A total of 382 prescriptions were included, and 109 Chinese medicines were used. Three most commonly used medicines were Pseudostellariae Radix (364), Poria (343) and Fritillariae Thunbergii Bulbus (336). The most commonly used medicine combinations were Pseudostellariae Radix-Poria (337), Fritillariae Thunbergii Bulbus-Pseudostellariae Radix (333) and Fritillariae Thunbergii Bulbus-Poria (327). There were 48 groups of associated medicines with confidence level of one. Ten core combinations and six new prescriptions were obtained by complex system entropy cluster analysis. Conclusion The mainly treatment method of advanced hepatocellular carcinoma by Professor Wu Yu is tonifying qi and spleen and resolving phlegm, mostly supplemented by regulating qi and removing stasis, resolving hard mass and removing toxicity. The method considers both manifestation and root cause, and it is useful for clinical reference.
|
|
|
|
|
|
[1] Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[3] Feng RM，Zong YN，Cao SM，et al. Current cancer situation in China：good or bad news from the 2018 global cancer statistics [J]. Cancer Commun（Lond），2019，39（1）：22.
[4] Zhou M，Wang H，Zeng X，et al. Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2019，394（10204）：1145-1158.
[5] 郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志，2019，41（1）：19-28.
[6] Forner A，Llovet JM，Bruix J. Hepatocellular carcinoma [J]. Lancet，2012，379（9822）：1245-1255.
[7] Zeng H，Chen W，Zheng R，et al. Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries [J]. Lancet Glob Health，2018， 6（5）：e555-e567.
[8] 程玉佩，张明香.中医药治疗原发性肝癌研究进展[J].辽宁中医药大学学报，2018，20（1）：167-169.
[9] 刘嘉辉，韦志辉，吕东勇，等.基于数据挖掘的名老中医治疗原发性肝癌用药规律研究[J].中华中医药杂志，2016， 31（1）：58-61.
[10] 原发性肝癌诊疗规范（2019年版）[J].中国实用外科杂志，2020，40（2）：121-138.
[11] Llovet JM，Brú C，Bruix J. Prognosis of hepatocellular carcinoma：the BCLC staging classification [J]. Semin Liver Dis，1999，19（3）：329-338.
[12] 高学敏.中药学[M].北京：中国中医药出版社，2019.
[13] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2015.
[14] 刘凯，王艳国.中医传承辅助平台在中医药研究中应用现状[J].山东中医杂志，2015，34（5）：392-394.
[15] 唐仕欢，申丹，卢朋，等.中医传承辅助平台应用评述[J].中华中医药杂志，2015，30（2）：329-331.
[16] 唐仕欢，陈建新，杨洪军，等.基于复杂系统熵聚类方法的中药新药处方发现研究思路[J].世界科学技术：中医药现代化，2009，11（2）：225-228.
[17] 明·张介宾.景岳全书[M].北京：中国中医药出版社，1994：278.
[18] 曲骞，吴煜.吴煜教授疏肝健脾法治疗肝癌经验探析[J].西部中医药，2018，31（6）：40-43.
[19] 袁菊花，吴煜.肝癌从痰论治[J].新中医，2012，44（3）：131-132.
[20] 清·李用粹.证治汇补[M].太原：山西科学技术出版社，2011：216.
[21] 清·周学海.读医随笔[M].北京：中国中医药出版社，2007：170.
[22] 张锡纯.医学衷中参西录（上、下）[M].石家庄：河北科学技术出版社，2017：559.
[23] 陈昭，陈伟韬，罗文汇，等.HPCE法研究土鳖虫镇痛作用与其指纹图谱的关系[J].中成药，2016，38（5）：1074-1077.
[24] 徐莉，窦家聪，尹雷，等.不同大孔树脂处理土鳖虫酶解液抗血栓作用研究[J].辽宁中医药大学学报，2016，18（3）：31-33.
[25] 康亚国.虫类药应用发微[J].辽宁中医杂志，2006，33（8）：1008-1009. |
|
|
|
